MATTHEW T WHITEHURST MD NPI 1457586208

NPI Details

Matthew T Whitehurst, MD is a medical oncology internal medicine in Fredericksburg, VA with 11 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. Matthew T Whitehurst, MD NPI is 1457586208. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE
Graduation Year:2015

The provider's business location address is:

4501 EMPIRE CT
FREDERICKSBURG, VA
ZIP 22408-949
Phone: (540) 371-0079

The NPI 1457586208 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram (HCPCS:Q5110)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, paclitaxel protein-bound particles, 1 mg (HCPCS:J9264)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, lanreotide, 1 mg (HCPCS:J1930)
• Injection, pemetrexed, not otherwise specified, 10 mg (HCPCS:J9305)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg (HCPCS:Q5107)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Magnesium level (HCPCS:83735)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, rituximab-arrx, biosimilar, (riabni), 10 mg (HCPCS:Q5123)
• Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg (HCPCS:Q5122)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Injection, etoposide, 10 mg (HCPCS:J9181)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Phosphate level (HCPCS:84100)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Unclassified drugs (HCPCS:J3490)
• Prealbumin (protein) level (HCPCS:84134)
• Urinalysis, manual test (HCPCS:81002)
• Adm sarscov2 100mcg/0.5ml3rd (HCPCS:0013A)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Vitamin d-3 level (HCPCS:82306)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Collection of blood sample from implanted device (HCPCS:36591)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Uric acid level, blood (HCPCS:84550)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Drawing of blood for a medical problem (HCPCS:99195)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 125 (HCPCS:86304)
• Coronavirus vaccine 14 (HCPCS:91313)
• Injection, fosnetupitant 235 mg and palonosetron 0.25 mg (HCPCS:J1454)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Injection, furosemide, up to 20 mg (HCPCS:J1940)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Fee covid-19 vac 14 res (HCPCS:0134A)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage (HCPCS:90694)
• Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report (HCPCS:93000)
• Stool analysis for blood, by peroxidase activity (HCPCS:82272)
• Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus (HCPCS:87426)
• Injection of drug or substance into vein (HCPCS:96374)
• Telephone medical discussion with physician, 21-30 minutes (HCPCS:99443)
• Haptoglobin (serum protein) level (HCPCS:83010)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Telephone medical discussion with physician, 11-20 minutes (HCPCS:99442)

The enumeration date for this NPI number is 5/22/2009 and was last updated on 12/19/2019.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: